Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 5.31
- Piotroski Score 6.00
- Grade Buy
- Symbol (BSX)
- Company Boston Scientific Corporation
- Price $83.80
- Changes Percentage (0.53%)
- Change $0.45
- Day Low $82.93
- Day High $83.86
- Year High $84.89
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 10/24/2024
- Fiscal Year End N/A
- Average Stock Price Target $78.00
- High Stock Price Target $118.00
- Low Stock Price Target $48.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $1.19
- Trailing P/E Ratio 64.8
- Forward P/E Ratio 64.8
- P/E Growth 64.8
- Net Income $1.59 B
Income Statement
Quarterly
Annual
Latest News of BSX
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Boston Scientific Corporation (BSX) Gains 44% YTD as Farapulse Launch Drives 17% Q2 Growth
Boston Scientific Corporation (BSX) is among the top healthcare stocks to buy according to hedge funds, with strong growth potential. Its recent product launch and revenue growth have positioned it fa...
By Yahoo! Finance | 19 hours ago -
Boston Scientific Corporation (BSX): Among Morgan Stanley's Best Stock Picks for 2025
Morgan Stanley's stock picks for 2025 include Boston Scientific Corporation (NYSE:BSX), a leading medical device manufacturer. BSX's innovative technologies like pulsed field ablation contribute to it...
By Yahoo! Finance | 2 weeks ago -
Is Boston Scientific Corporation (BSX) The Best Blue Chip Stock Under $100?
A list of top Blue Chip Stocks under $100 includes Boston Scientific Corporation (NYSE:BSX), a company with strong growth prospects in electrophysiology and structural heart devices. Analysts are opti...
By Yahoo! Finance | 1 month ago
